To identify whether the levels of IL-10 are increased in pancreatic cancer patients compared to benign pancreatic disease patients, we measured the concentration of this cytokine, known to modulate tumour-specific T cell responses, in the plasma of 34 PC patients, 15 patients with benign pancreatic disease and 13 healthy donors. This evidence concerns the gene IL10 and pancreatic neoplasm.